Drug donation policy for Durvalumab in 2025

Durvalumab/Infinifer (Durvalumab), as a domestically marketed immunotherapy drug, is often used for the consolidation treatment of non-small cell lung cancer after radiotherapy and chemotherapy. Although it has been officially launched in China, it has not yet been included in the national medical insurance directory, making patients and their families more concerned about its actual medication cost and whether there is a drug donation policy. Current public information shows that the domestic drug donation policy for this drug has not been made public and clear, and no manufacturer has officially released a unified assistance plan. Therefore, it is still in the stage of "the policy has not been announced and the details have not been determined."

Because they are not covered by medical insurance, the cost of drugs may cause certain financial pressure on some patients. Therefore, Information such as "donated drugs", "assistance plan" and "drug subsidies" have also become keywords that are frequently searched by patients. Generally speaking, if imported immune drugs are not included in medical insurance, whether pharmaceutical companies launch patient assistance programs usually depends on multiple factors, including domestic launch time, marketing stage, indication coverage, hospital access status, and drug negotiation strategies. Sometimes in different hospitals or provinces and cities, there may be phased, regional or short-term pilot drug donation programs, but these are not nationally unified policies and do not have long-term stability.

Others in the past Before PD-1/PD-L1 drugs were included in medical insurance, there were indeed forms of drug donations launched by foundations or pharmaceutical companies in cooperation, such as "buy a few, get a few free", "treatment assistance", etc. However, similar policies have not yet been announced for durvalumab, so patients should be cautious about information from unofficial channels. If it enters medical insurance in the future, its cost structure will change, and the price will be directly negotiated by the national medical insurance, resulting in a significant reduction in patient costs and the importance of the free drug policy.

Reference materials:https://www.imfinzi.com/